• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content

Medxy AI

  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
Corynebacterium diphtheriae Outbreak among Migrants in Europe: Clinical, Epidemiologic, and Microbiologic Insights
Posted inClinical Updates Wellness & Lifestyle

Corynebacterium diphtheriae Outbreak among Migrants in Europe: Clinical, Epidemiologic, and Microbiologic Insights

Posted by By MedXY 08/01/2025
A multicountry outbreak of diphtheria among migrants in Europe raised concerns about cutaneous and respiratory disease, cross-border spread, and emerging antibiotic resistance. Genomic analysis revealed multiclonal transmission and resistance challenges for standard therapies.
Read More
Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Posted inClinical Updates Wellness & Lifestyle

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Posted by By MedXY 08/01/2025
Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.
Read More
Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial
Posted inClinical Updates Wellness & Lifestyle

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

Posted by By MedXY 08/01/2025
A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.
Read More
Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade
Posted inClinical Updates Wellness & Lifestyle

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

Posted by By MedXY 08/01/2025
Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.
Read More
Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial
Posted inClinical Updates Wellness & Lifestyle

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

Posted by By MedXY 08/01/2025
A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.
Read More
Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial
Posted inClinical Updates Wellness & Lifestyle

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

Posted by By MedXY 08/01/2025
Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.
Read More
Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study
Posted inClinical Updates Medical News

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

Posted by By MedXY 08/01/2025
A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.
Read More
Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients
Posted inClinical Updates Medical News

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

Posted by By MedXY 08/01/2025
A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.
Read More
Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results and Clinical Implications
Posted inClinical Updates Medical News

Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results and Clinical Implications

Posted by By MedXY 08/01/2025
A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.
Read More
First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial
Posted inClinical Updates Wellness & Lifestyle

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

Posted by By MedXY 08/01/2025
Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.
Read More
Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications
Posted inClinical Updates Wellness & Lifestyle

Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications

Posted by By MedXY 08/01/2025
Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.
Read More
As-Needed Albuterol–Budesonide Therapy in Mild Asthma: Clinical Impact and Comparative Evidence
Posted inClinical Updates Wellness & Lifestyle

As-Needed Albuterol–Budesonide Therapy in Mild Asthma: Clinical Impact and Comparative Evidence

Posted by By MedXY 08/01/2025
As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.
Read More
Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials
Posted inClinical Updates

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials

Posted by By MedXY 08/01/2025
Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusion.
Read More
Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study
Posted inClinical Updates Wellness & Lifestyle

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

Posted by By MedXY 08/01/2025
Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.
Read More
Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis
Posted inClinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis

Posted by By MedXY 08/01/2025
A recent multicenter trial demonstrates methotrexate's noninferiority to prednisone in improving lung function at 24 weeks in pulmonary sarcoidosis, with distinct side-effect profiles informing treatment choices.
Read More
Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation
Posted inClinical Updates Wellness & Lifestyle

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

Posted by By MedXY 08/01/2025
Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.
Read More
Multidose Ondansetron After Emergency Visits: Reducing Gastroenteritis Severity in Children
Posted inClinical Updates Wellness & Lifestyle

Multidose Ondansetron After Emergency Visits: Reducing Gastroenteritis Severity in Children

Posted by By MedXY 08/01/2025
A randomized trial shows that multidose ondansetron after pediatric ED visits for gastroenteritis reduces moderate-to-severe illness, though impact on vomiting duration and healthcare utilization is limited.
Read More
Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort
Posted inClinical Updates Wellness & Lifestyle

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

Posted by By MedXY 08/01/2025
A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.
Read More
Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial
Posted inClinical Updates Wellness & Lifestyle

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

Posted by By MedXY 07/31/2025
Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.
Read More
Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data
Posted inClinical Updates Wellness & Lifestyle

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

Posted by By MedXY 07/31/2025
Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.
Read More

Posts pagination

Previous page 1 … 65 66 67 68 69 … 80 Next page
  • Immunogenicity and Safety of the VLA15 Lyme Borreliosis Vaccine Across Age Groups: A Phase 2 Randomised Controlled Trial and Integrative Review
  • MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management
  • Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial
  • Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
  • Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence
Post You Might Like
Posted inClinical Updates Wellness & Lifestyle
Immunogenicity and Safety of the VLA15 Lyme Borreliosis Vaccine Across Age Groups: A Phase 2 Randomised Controlled Trial and Integrative Review
Posted by By MedXY 09/21/2025
Posted inClinical Updates Wellness & Lifestyle
MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management
Posted by By MedXY 09/21/2025
Posted inClinical Updates Wellness & Lifestyle
Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial
Posted by By MedXY 09/21/2025
Posted inClinical Updates Wellness & Lifestyle
Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
Posted by By MedXY 09/21/2025
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging AI artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity MASH mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch thử nghiệm lâm sàng tirzepatide type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top